Last reviewed · How we verify
SNX-5422 Mesylate Hsp90 inhibitor
SNX-5422 Mesylate Hsp90 inhibitor is a Small molecule drug developed by Esanex Inc.. It is currently in Phase 1 development.
At a glance
| Generic name | SNX-5422 Mesylate Hsp90 inhibitor |
|---|---|
| Sponsor | Esanex Inc. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- SNX-5422 to Treat Solid Tumor Cancers and Lymphomas (PHASE1)
- Safety Study Of SNX-5422 To Treat Solid Tumor Cancers And Lymphomas (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- SNX-5422 Mesylate Hsp90 inhibitor CI brief — competitive landscape report
- SNX-5422 Mesylate Hsp90 inhibitor updates RSS · CI watch RSS
- Esanex Inc. portfolio CI
Frequently asked questions about SNX-5422 Mesylate Hsp90 inhibitor
What is SNX-5422 Mesylate Hsp90 inhibitor?
SNX-5422 Mesylate Hsp90 inhibitor is a Small molecule drug developed by Esanex Inc..
Who makes SNX-5422 Mesylate Hsp90 inhibitor?
SNX-5422 Mesylate Hsp90 inhibitor is developed by Esanex Inc. (see full Esanex Inc. pipeline at /company/esanex-inc).
What development phase is SNX-5422 Mesylate Hsp90 inhibitor in?
SNX-5422 Mesylate Hsp90 inhibitor is in Phase 1.
Related
- Manufacturer: Esanex Inc. — full pipeline
- Compare: SNX-5422 Mesylate Hsp90 inhibitor vs similar drugs
- Pricing: SNX-5422 Mesylate Hsp90 inhibitor cost, discount & access